GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Newron Pharmaceuticals SpA (XSWX:NWRN) » Definitions » Price-to-Owner-Earnings

Newron Pharmaceuticals SpA (XSWX:NWRN) Price-to-Owner-Earnings : (As of Apr. 29, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Newron Pharmaceuticals SpA Price-to-Owner-Earnings?

As of today (2024-04-29), Newron Pharmaceuticals SpA's share price is CHF7.28. Newron Pharmaceuticals SpA does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Newron Pharmaceuticals SpA's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of Newron Pharmaceuticals SpA was 25.61. The lowest was 11.44. And the median was 12.91.


XSWX:NWRN's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 32.12
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-04-29), Newron Pharmaceuticals SpA's share price is CHF7.28. Newron Pharmaceuticals SpA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was CHF-0.87. Therefore, Newron Pharmaceuticals SpA's PE Ratio for today is At Loss.

As of today (2024-04-29), Newron Pharmaceuticals SpA's share price is CHF7.28. Newron Pharmaceuticals SpA's EPS without NRI for the trailing twelve months (TTM) ended in was CHF-0.87. Therefore, Newron Pharmaceuticals SpA's PE Ratio without NRI for today is At Loss.


Newron Pharmaceuticals SpA Price-to-Owner-Earnings Historical Data

The historical data trend for Newron Pharmaceuticals SpA's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Newron Pharmaceuticals SpA Price-to-Owner-Earnings Chart

Newron Pharmaceuticals SpA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Newron Pharmaceuticals SpA Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Newron Pharmaceuticals SpA's Price-to-Owner-Earnings

For the Biotechnology subindustry, Newron Pharmaceuticals SpA's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Newron Pharmaceuticals SpA's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Newron Pharmaceuticals SpA's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Newron Pharmaceuticals SpA's Price-to-Owner-Earnings falls into.



Newron Pharmaceuticals SpA Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Newron Pharmaceuticals SpA's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=7.28/-0.49
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Newron Pharmaceuticals SpA  (XSWX:NWRN) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Newron Pharmaceuticals SpA Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Newron Pharmaceuticals SpA's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Newron Pharmaceuticals SpA (XSWX:NWRN) Business Description

Traded in Other Exchanges
Address
Via Antonio Meucci 3, Bresso, Milan, ITA, 20091
Newron Pharmaceuticals SpA is a biopharmaceutical company focused on the development of therapies for patients with diseases of the central and peripheral nervous system. Geographically the research and development activities are performed in Italy and the United States.
Executives
Patrick Langlois Supervisory Board

Newron Pharmaceuticals SpA (XSWX:NWRN) Headlines

No Headlines